Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
All participants:
\- Has a BMI ≥18.0 and ≤40.0 kg/m\^2
Participants with severe or moderate RI:
With the exception of RI, is sufficiently healthy for study participation
Has stable renal function with no clinically significant change in renal status at least 29 days prior to dosing and is not currently or has not been previously on dialysis for at least 1 year
Participants with normal renal function:
\- Is medically healthy
You may not be if
All participants:
Has a history of cancer (malignancy)
Has positive results for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus
Has had major surgery and/or donated or lost significant volume of blood within 56 days prior to dosing
Participants with severe or moderate RI:
Has a history or presence of renal artery stenosis
Has a renal transplant or nephrectomy
Clareo Health | A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)
